Shares of Advaxis (NASDAQ:ADXS) are up a whopping 72%, selling for $10.20 this morning after the company released improved data for its personalized cancer vaccine candidate ADXS-NEO.
The stock is up about 32% year to date amid various news developments. On Friday, ADXS had a reverse stock split in the ratio of 15-for-1, following which shareholders in the company will get 15 shares for every stock held (as of March 28th, 2019).
Preliminary results from a Phase 1 study of ADXS-NEO showed “substantial” anti-tumor activity, including T cell responses to neoantigens and antigen spreading, ...
Read The Full Article On StreetSignals.com
Get the latest stock market news on StreetSignals. Follow public companies and get free stock research reports and stock market analysis data and stock tips.
All content provided by StreetSignals is subject to our Terms Of Use and Disclaimer.